Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
This study shows that combining tislelizumab and low-dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF-based molecular markers reflect genomic evolution and predict prognosis. Increased CD163<sup>+</sup> cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF-15 levels may further suppress antitumor immunity, facilitating immune escape.
Authors
- Chaojie Bu
- Chunxiao Ma (ORCID: https://orcid.org/0000-0002-1322-2863)
- Guanzheng Liu (ORCID: https://orcid.org/0000-0002-3692-0314)
- Ya Shi (ORCID: https://orcid.org/0000-0002-1988-2280)
- Jiubing Zhang (ORCID: https://orcid.org/0009-0000-2549-4068)
- Xingyao Bu (ORCID: https://orcid.org/0000-0002-8034-6858)
- M Q Wang
- Dayang Wang
- Yushuai Gao
- Minghao Li
- Ziyue Zhang
- Shaobin Wei
- Zhaoyue Yan
- Guangming Lv
Institutions
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1002/cncr.70253
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00